This article summarized the latest R&D progress of Nicorandil, the mechanism of action for Nicorandil, and the drug target R&D trends for Nicorandil.

On December 11, 2023, This ongoing phase 1, 3+3 dose-escalation/expansion study (NCT04279847) to evaluate the safety and tolerability of INCB057643 will be reported at the ASH Congress.

On October 26th, 2023, KangaBio announced that the FDA has formally approved their clinical trial application for the independently developed KGX101, a fusion protein recombined with IL-12 Fc for intravenous injection. Clinical trials will be held simultaneously in Australia and the US.

The Androgen Receptor (AR) regulates prostate homeostasis and cancer cell survival. AR-targeted therapy boosts survival rates in advanced prostate cancer patients ineffectively cured by surgery or radiation.

This article summarized the latest R&D progress of Nitisinone, the Mechanism of Action for Nitisinone, and the drug target R&D trends for Nitisinone.

The latest research trial study of CBP-501 for the treatment of metastatic PDAC reported at the ESMO Congress exhibits promising therapeutic benefits.

Sensei Biotherapeutics, Inc. revealed initial results from its Phase 1/2 trial's sole therapy dose-increase part for SNS-101, a selectively active human antibody targeting the VISTA immune checkpoint.

AMPK is a critical metabolic regulator, responsible for maintaining and restoring energy balance at the cellular and physiological levels. Studying AMPK targets and their microenvironment helps clarify how AMPK restores energy homeostasis.

This article summarized the latest R&D progress of Nitroxoline, the mechanism of action for Nitroxoline, and the drug target R&D trends for Nitroxoline.

On October 20, 2023, the first-in-human trial of BDC-1001 in advanced HER2-positive solid tumors was reported at the ESMO Congress.

REGENXBIO Inc. reveals positive additional results from ongoing Phase II ALTITUDE® study. The study pertains to ABBV-RGX-314, expected for treating diabetic retinopathy except center-involved diabetic macular edema, and is given through in-office suprachoroidal delivery.

AKT (Protein Kinase B), a pivotal player in PI3K/AKT/m-TOR signaling pathway, is a prospective drug target clinically. Its activation is crucial for cell survival and growth, implicating in tumorigenesis and metastasis. Research indicates AKT over-activation in over 50% of tumors.